The US Food and Drug Administration (FDA) has granted fast track designation to US-based Annexon Biosciences' ANX005, intended to treat Guillain-Barre Syndrome (GBS), it was reported Tuesday.
ANX005 is a clinical-stage investigational monoclonal antibody for the treatment of patients suffering from autoimmune and neurodegenerative disorders. It is designed to block C1q and the complete classical complement pathway.
The company has reportedly completed a phase 1b clinical study of the product and aims to advance ANX005 into later-stage clinical trials in GBS disease. It is also planning to develop the product for additional autoimmune and neurodegenerative diseases.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca